While MEKi-induced AKT activation tends to occur in BC cell lines having normal PTEN in these studies, it remains unclear if such adaptive response also happens in a PTEN-null background or if the already enhanced basal AKT activation would buffer the potential effect coming from breaking the MEK-EGFR-PI3K negative feedback. The gene discussed is PIK3CD; the disease is breast cancer.